ClinicalTrials.gg
CompletedNCT01777152ECHELON-2Updated Nov 30, 2021Results posted

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

A Phase 3 interventional study of brentuximab vedotin and doxorubicin in Anaplastic Large-Cell Lymphoma, Non-Hodgkin Lymphoma and T-Cell Lymphoma, sponsored by Seagen Inc.. Completed at 144 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-30.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic — 1 open to participants now, 2 under way, none of them phase 3. Brentuximab Vedotin · Lymphoma, Large-Cell, Anaplastic.

Enrollment
Largest of 21
452 · median 44
Started
2013
with 3 others
Phase 3
Only one
of the 21
Registered
10th of 21
by date
Lead sponsor
9 of 21
Seagen Inc.

Among the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, this one has the largest enrollment, is one of 4 that started in 2013, is the only one in phase 3, and was the 10th registered.

Lymphoma, Large-Cell, Anaplastic

397 studies on the registry are indexed under Lymphoma, Large-Cell, Anaplastic; 26 are open to participants now.

Browse Lymphoma, Large-Cell, Anaplastic studies →

Open to participants now

1 of the 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Brentuximab Vedotin

Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Lymphoma, Large-Cell, Anaplastic studies recruiting now, 12 (57%) set no upper age limit and 6 (29%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing Brentuximab Vedotin in Lymphoma, Large-Cell, Anaplastic, or all of them as a file.
02

Study summary

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

03

Conditions studied

  • Anaplastic Large-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • T-Cell Lymphoma

Keywords

  • Antibodies, Monoclonal
  • Antibody-Drug Conjugate
  • Antigens, CD30
  • Drug Therapy
  • Hematologic Diseases
  • Lymphoma
  • Monomethyl auristatin E
  • Lymphoma, T-Cell
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Large-Cell, Anaplastic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with newly diagnosed, CD30-positive mature T-cell lymphomas
  • Fluorodeoxyglucose (FDG)-avid disease by PET and of at least 1.5 cm by CT
  • (ECOG) performance status less than or equal to 2

Exclusion criteria

Exclusion Criteria:

  • History of another primary invasive that has not been in remission for at least 3 years
  • Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides
  • History of progressive multifocal leukoencephalopathy (PML)
  • Cerebral/meningeal disease related to the underlying malignancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
452 participants (actual)

Study arms

  • Active comparator
    CHOP

    cyclophosphamide, doxorubicin, vincristine, and prednisone

    Drug: doxorubicin · Drug: prednisone · Drug: vincristine · Drug: cyclophosphamide

  • Experimental
    A+CHP

    brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone

    Drug: brentuximab vedotin · Drug: doxorubicin · Drug: prednisone · Drug: cyclophosphamide

Interventions

  • 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles

    Also known as: Adcetris; SGN-35

  • 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

  • 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles

  • 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles

  • 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

06

What researchers measure

Primary outcomes

  1. Progression-free Survival Per Independent Review Facility (IRF)

    The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.

    Time frame: Up to 60 months

Secondary outcomes

  1. Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)

    The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.

    Time frame: Up to 60 months

  2. Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)

    The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to 8.34 months

  3. Overall Survival (OS)

    The time from randomization to death due to any cause.

    Time frame: Up to 90 months

  4. Objective Response Rate (ORR) Per IRF at End of Treatment

    The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.

    Time frame: Up to 8.34 months

  5. Incidence of Adverse Events (AEs)

    Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 8.28 months

  6. Incidence of Laboratory Abnormalities

    Number of participants who experienced a Grade 3 or higher laboratory toxicity.

    Time frame: Up to 8.28 months

07

Results

Posted Jul 30, 2019

Participant flow

Jan2013-Nov2016

Participant flow — Overall Study
MilestoneA+CHPCHOP
Started226226
Completed131116
Not completed95110
Withdrew: Withdrawal by subject2216
Withdrew: Lost to follow-up35
Withdrew: Death6889
Withdrew: Not eligible, no study drug received10
Withdrew: Change of diagnosis10

Outcome measures

PrimaryProgression-free Survival Per Independent Review Facility (IRF)

The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.

Time frame:
Up to 60 months
Reported as:
Median · months
Progression-free Survival Per Independent Review Facility (IRF)
monthsA+CHPCHOP
Progression-free Survival Per Independent Review Facility (IRF)48.20 (8.87 to NA)20.80 (4.70 to NA)
SecondaryProgression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)

The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.

Time frame:
Up to 60 months
Reported as:
Median · months
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
monthsA+CHPCHOP
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)55.66 (15.61 to NA)32.03 (4.57 to NA)
SecondaryComplete Remission (CR) Rate Per IRF at End of Treatment (EOT)

The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to 8.34 months
Reported as:
Count of participants · Participants
Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)
ParticipantsA+CHPCHOP
Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)153126
SecondaryOverall Survival (OS)

The time from randomization to death due to any cause.

Time frame:
Up to 90 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsA+CHPCHOP
Overall Survival (OS)NA (0.0 to 86.5)NA (0.1 to 90.0)
SecondaryObjective Response Rate (ORR) Per IRF at End of Treatment

The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.

Time frame:
Up to 8.34 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Per IRF at End of Treatment
ParticipantsA+CHPCHOP
Objective Response Rate (ORR) Per IRF at End of Treatment188163
SecondaryIncidence of Adverse Events (AEs)

Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to 8.28 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs)
ParticipantsA+CHPCHOP
Any treatment-emergent AE221221
Blinded study treatment-related AE201193
CHP treatment-related AE198205
Any serious adverse event (SAE)8787
Blinded study treatment-related SAE5845
CHP treatment-related SAE6253
Treatment discontinuations due to AE1415
Treatment discontinuations due to blinded study treatment-related AE1010
Treatment discontinuations due to CHP treatment-related AE87
SecondaryIncidence of Laboratory Abnormalities

Number of participants who experienced a Grade 3 or higher laboratory toxicity.

Time frame:
Up to 8.28 months
Reported as:
Count of participants · Participants
Incidence of Laboratory Abnormalities
ParticipantsA+CHPCHOP
Any Chemistry Test2523
Alanine Aminotransferase High31
Albumin Low23
Alkaline Phosphatase High10
Calcium Low11
Glucose High86
Phosphate Low43
Potassium High02
Potassium Low32
Sodium High10
Sodium Low46
Urate High52
Any Hematology Test6878
Absolute Neutrophil Count Low1719
Hemoglobin High10
Hemoglobin Low913
Leukocytes Low1221
Lymphocytes High01
Lymphocytes Low5261
Neutrophils Low1719
Platelets Low11

Adverse events

Collected over Non-serious AEs followed up to 8 months. Serious AEs followed up to 90 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A+CHP67/223 (30%)89/223 (39.9%)220/223 (98.7%)
CHOP89/226 (39.4%)90/226 (39.8%)218/226 (96.5%)
A+CHP Subgroup1/3 (33.3%)——
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventA+CHPCHOPA+CHP Subgroup
Febrile neutropeniaBlood and lymphatic system disorders32/22326/226—
PneumoniaInfections and infestations11/2233/226—
Anaplastic large cell lymphoma T- and null-cell typesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/22311/226—
PyrexiaGeneral disorders9/2238/226—
NeutropeniaBlood and lymphatic system disorders8/2236/226—
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/2236/226—
PneumonitisRespiratory, thoracic and mediastinal disorders5/2230/226—
SepsisInfections and infestations5/2234/226—
DiarrhoeaGastrointestinal disorders4/2233/226—
NauseaGastrointestinal disorders1/2234/226—
Most frequent other events
Showing 10 of 61
Most frequent other events
EventA+CHPCHOPA+CHP Subgroup
NauseaGastrointestinal disorders114/22391/226—
Peripheral sensory neuropathyNervous system disorders112/223108/226—
ConstipationGastrointestinal disorders98/22394/226—
DiarrhoeaGastrointestinal disorders93/22355/226—
NeutropeniaBlood and lymphatic system disorders87/22381/226—
PyrexiaGeneral disorders86/22374/226—
FatigueGeneral disorders83/22380/226—
HypertensionVascular disorders71/22368/226—
AnaemiaBlood and lymphatic system disorders64/22349/226—
Night sweatsSkin and subcutaneous tissue disorders46/22363/226—

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)A+CHPCHOPTotal
<=18 years000
Between 18 and 65 years157156313
>=65 years6970139
Age, Continuous
Age, Continuous(years)A+CHPCHOPTotal
Median58 (18 to 85)58 (18 to 83)58 (18 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)A+CHPCHOPTotal
Female9375168
Male133151284
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)A+CHPCHOPTotal
Hispanic or Latino10414
Not Hispanic or Latino186193379
Unknown or Not Reported302959
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)A+CHPCHOPTotal
Asian455499
Black or African American12618
Native Hawaiian or Other Pacific Islander101
White139142281
Other325
Unknown262248
Region of Enrollment
Region of Enrollment(Participants)A+CHPCHOPTotal
United States7057127
Japan202343
South Korea172340
Italy172037
France181836
Germany151227
Spain151126
Czechia101222
United Kingdom71421
Australia6814
Denmark9514
Israel8412
Hungary459
Taiwan, Province Of China549
Poland257
Canada336
Romania022
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)A+CHPCHOPTotal
Grade 08593178
Grade 19086176
Grade 2514798
08

Study locations

144 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • City of Hope National Medical Center
    Duarte, California 91010-3000, United States
  • Stanford Cancer Center
    Stanford, California 94305, United States
  • Shands Cancer Center / University of Florida
    Gainesville, Florida 32610, United States
  • Orlando Health, Inc.
    Orlando, Florida 32806, United States
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
  • Cardinal Bernardin Cancer Center / Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Holden Comprehensive Cancer Center / University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Cancer Center
    Westwood, Kansas United States, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center - Basking Ridge
    Basking Ridge, New Jersey 07920, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Albert Einstein Cancer Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering Cancer Center - Commack
    Commack, New York 11725, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • Columbia University Medical Center
    New York, New York 10022, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • James P. Wilmot Cancer Center / University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Jewish Hospital, The
    Cincinnati, Ohio 45236, United States
  • Cleveland Clinic, The
    Cleveland, Ohio 44195, United States
  • Mercy Clinic Oncology
    Oklahoma City, Oklahoma 73120, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania United States, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 30384, United States
  • Charles A. Sammons Cancer Center / Baylor University Medical Center
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center / University of Texas
    Houston, Texas 77030-4095, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Virginia Commonwealth University Medical Center
    Richmond, Virginia 23298, United States
  • Benaroya Research Institute/Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Seattle Cancer Care Alliance / University of Washington
    Seattle, Washington 98109-1023, United States
  • Royal Adelaide Hospital
    Adelaide, 5000, Australia
  • Moorabbin Hospital
    Bentleigh East, 3165, Australia
  • Icon Cancer Care Chermside
    Chermside, 4032, Australia
  • Icon Cancer Care South Brisbane
    Chermside, 4032, Australia
  • Icon Cancer Care Southport
    Chermside, 4032, Australia
  • Icon Cancer Care Wesley
    Chermside, 4032, Australia
  • Monash Medical Centre
    Clayton, 3168, Australia
  • Concord Repatriation General Hospital
    Concord, 2139, Australia
  • St. Vincent's Hospital Sydney
    Darlinghurst, 2010, Australia
  • St Vincent's Public Hospital Sydney - Fitzroy
    Fitzroy, 3065, Australia
  • Western Hospital
    Footscray, 3011, Australia
  • Austin Health
    Heidelberg, 3084, Australia
  • Calvary Mater Newcastle
    Waratah, 2298, Australia
  • McGill University Department of Oncology / McGill University Health Centre
    Montreal, H3H 2R9, Canada
  • Jewish General Hospital
    Montreal, H3T 1E2, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, M4N 3M5, Canada
  • British Columbia Cancer Agency - Vancouver Centre
    Vancouver, V5Z 4E6, Canada
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove-oddeleni klinicke hematologie
    Hradec Kralove, 500 05, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava - Poruba, 708 52, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Aarhus University Hospital
    Aarhus C., 8000, Denmark
  • Rigs Hospiltalet
    Copenhagen, DK 2100, Denmark
  • Odense University Hospital
    Odense C, 5000, Denmark
  • Hôpital Henri Mondor
    Créteil, 94010, France
  • CHD Vendée, Site de La Roche-sur-Yon, Les Oudairies
    La Roche-sur-Yon Cedex 9, 85925, France
  • Centre Hospitalier Universitaire de Grenoble
    La Tronche, 38700, France
  • Clinique Victor Hugo
    Le Mans, 72000, France
  • CHRU de Lille
    Lille cedex, 59037, France
  • Centre Hospitalier Universitaire (CHU) De Limoges - Hopital Dupuytren
    Limoges Cedex, 87042, France
  • Centre Hospitalier Universitaire Nantes-Hotel Dieu
    Nantes cedex 1, 44093, France
  • Hopital Saint-Louis / Service d'Hematologie
    Paris Cedex 10, 75475, France
  • Groupe Hospitalier Pitié-Salpétrière
    Paris, 75013, France
  • Groupe Hospitalier du Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite Cedex, 69495, France
  • Centre Hospitalier Universitaire de Poitiers
    Poitiers Cedex, 86021, France
  • Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou
    Rennes Cedex 9, 35033, France
  • Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer
    Rouen, 76038, France
  • Charite Universitatsmedizin Berlin
    Berlin, 10117, Germany
  • Charite Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Klinikum Chemnitz gGmbH
    Chemnitz, 09113, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Krankenhaus Nordwest GmbH
    Frankfurt am Main, 60488, Germany
  • Georg-August-Universität Göttingen
    Göttingen, 37075, Germany
  • Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Universitätsklinikum des Saarlandes
    Homburg/Saar, 66421, Germany
  • Klinik für Innere Medizin II, Friedrich-Schiller-Universität
    Jena, 07747, Germany
  • Universitatsklinikum Koln
    Köln, 50937, Germany
  • Klinikum der Ludwig-Maximilians-Universität München
    München, 81377, Germany
  • Klinikum Nürnberg
    Nürnberg, 90419, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Debreceni Egyetem
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mór Oktató Kórház
    Kaposvár, 7400, Hungary
  • Markusovszky Egyetemi Oktatokorhaz
    Szombathely, 9700, Hungary
  • Soroka Medical Center, Dept. of Oncology
    Beer Sheva, 84101, Israel
  • Rambam Health Corp.
    Haifa, 31096, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petach Tikva, 49414, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Azienda Ospedaliera SS. Antonio E. Biagio E. Cesare Arrigo di Alessandria
    Alessandria, 15121, Italy
  • Azienda Ospedaliera Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Instituto di Ematologia ed Oncologia Medica
    Bologna, 40138, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliera-Universitaria Vittorio Emanuele-Ferrarotto-Santo Bambino
    Catania, 95124, Italy
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy

Showing the first 100 of 144 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trumper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. PubMed 35470385 ↗
  • Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum In: Lancet. 2019 Jan 19;393(10168):228. doi: 10.1016/S0140-6736(18)33123-4. PubMed 30522922 ↗
  • Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18. PubMed 25135998 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2013 to primary completion in Aug 2018, 66 months.

Results were first posted in Jul 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2013
First posted
Jan 28, 2013
StartActual
Jan 31, 2013
Primary completionActual
Aug 15, 2018
CompletionActual
Oct 2, 2020
Results first posted
Jul 30, 2019
Last update
Nov 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01777152
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
Jan 31, 2013
Primary completion
Aug 15, 2018
Completion
Oct 2, 2020
Results posted
Jul 30, 2019
Last update
Nov 30, 2021

Study contacts

Thomas Manley, MD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion